BBR Partners LLC Purchases 155,000 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)

BBR Partners LLC increased its position in shares of 2seventy bio, Inc. (NASDAQ:TSVT) by 620.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 180,000 shares of the company’s stock after buying an additional 155,000 shares during the period. BBR Partners LLC’s holdings in 2seventy bio were worth $850,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. SkyView Investment Advisors LLC boosted its position in 2seventy bio by 25.0% during the second quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock valued at $48,000 after acquiring an additional 2,500 shares during the last quarter. Nisa Investment Advisors LLC bought a new stake in shares of 2seventy bio during the 2nd quarter valued at about $52,000. GSA Capital Partners LLP acquired a new stake in 2seventy bio during the third quarter worth approximately $64,000. Intech Investment Management LLC bought a new stake in 2seventy bio in the third quarter worth approximately $69,000. Finally, SG Americas Securities LLC acquired a new position in 2seventy bio in the third quarter valued at approximately $80,000. Institutional investors own 93.90% of the company’s stock.

2seventy bio Stock Performance

2seventy bio stock opened at $3.96 on Thursday. The stock has a market capitalization of $204.30 million, a price-to-earnings ratio of -2.15 and a beta of 1.78. 2seventy bio, Inc. has a 52-week low of $1.67 and a 52-week high of $6.40. The stock’s 50 day moving average price is $4.55 and its two-hundred day moving average price is $4.43.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.